Gynesonics Announces New SMART OS™ Software Technology for Sonata® System Treatment of Uterine Fibroids REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Gynesonics Inc., a medical device company focused on the development of minimally invasive solutions for symptomatic uterine fibroids,...

Gynesonics Announces Key Executive Appointments to Further Accelerate and Expand Adoption of the Sonata Treatment Gynesonics announces key executive appointments to further accelerate and expand adoption of the Sonata Treatment.

Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids Reaches Patient Milestones in the U.S. and Globally Gynesonics' Sonata® Procedure has been used to treat over 1,000 women in the United States and approximately 6,500 women globally.